search icon
      blog search icon

      MacroGenics Stock Price History and Quote Analysis: Insights for Investors

      MacroGenics, Inc.



      0.15 (2.00%)

      At Close: 4:00 PM

      MacroGenics Stock Price Graph

      • 1D
      • 5D
      • 1M
      • 3M
      • 6M
      • 1Y
      • YTD
      • All

      MacroGenics Stock Price Today

      MacroGenics, Inc. (MGNX) stock rallied over 3.52% intraday to trade at $7.65 a share on NASDAQ. The stock opened with a loss of -33.33% at $5.00 and touched an intraday high of $5.04, rising 2.00% against the last close of $7.50. The MacroGenics, Inc. in stock market went to a low of $4.90 during the session.

      MacroGenics Stock Snapshot


      Prev. Close

      474.53 Million

      Market Cap


      Day Low




      Number of Shares


      Day High


      P/E ratio


      EPS (TTM)


      Cash Flow per Share


      Free Float in %


      Book Value



      MacroGenics Stock Price History Chart


      Contact Details

      9704 Medical Center Drive
      Rockville, MD 20850


      Contact #:301 251 5172

      Company Information



      Sales or Revenue$121.13 Million

      5Y Sales Change15.66%

      Fiscal Year EndsDec. 2022



      About Company

      MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.


      Frequently Asked Questions


      What is the current MacroGenics, Inc. (MGNX) stock price?

      MacroGenics, Inc. (NASDAQ: MGNX) stock price is $7.65 in the last trading session. During the trading session, MGNX stock reached the peak price of $5.04 while $4.90 was the lowest point it dropped to. The percentage change in MGNX stock occurred in the recent session was 3.52% while the dollar amount for the price change in MGNX stock was $0.26.


      MGNX's industry and sector of operation?

      The NASDAQ listed MGNX is part of Biotechnology industry that operates in the broader Healthcare sector. MacroGenics, Inc. , a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States.


      Who are the executives of MGNX?

      Dr. Christopher Shayne James M.D.
      Vice President of Investor Relations & Corporation Communications
      Dr. Ezio Bonvini
      Senior Vice President of Research & Chief Scientific Officer
      Mr. James Karrels
      Senior Vice President, Chief Financial Officer & Corporation Sec.
      Dr. Stephen L. Eck M.D., Ph.D.
      Senior Vice President of Clinical Devel. & Chief Medical Officer


      How MGNX did perform over past 52-week?

      MGNX's closing price is 2.35% higher than its 52-week low of $4.29 where as its distance from 52-week high of $7.9 is -0.07%.


      How many employees does MGNX have?

      Number of MGNX employees currently stands at N/A. MGNX operates from 9704 Medical Center Drive, Rockville, MD 20850, US.


      Link for MGNX official website?

      Official Website of MGNX is:


      How do I contact MGNX?

      MGNX could be contacted at phone #301 251 5172 and can also be accessed through its website. MGNX operates from 9704 Medical Center Drive, Rockville, MD 20850, US.


      How many shares of MGNX are traded daily?

      MGNX stock volume for the day was 477061.00 shares. The average number of MGNX shares traded daily for last 3 months was 593.17 Thousands.


      What is the market cap of MGNX currently?

      The market value of MGNX currently stands at $474.53 Million with its latest stock price at $7.65 and N/A of its shares outstanding.